138 related articles for article (PubMed ID: 20538289)
1. Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Raval M; Frank PG; Laury-Kleintop L; Yan G; Lanza-Jacoby S
J Surg Res; 2010 Oct; 163(2):e113-22. PubMed ID: 20538289
[TBL] [Abstract][Full Text] [Related]
2. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
Jacob S; Laury-Kleintop L; Lanza-Jacoby S
J Surg Res; 2008 May; 146(1):135-42. PubMed ID: 17950326
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
[TBL] [Abstract][Full Text] [Related]
4. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ
Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
Zheng X; Cui XX; Avila GE; Huang MT; Liu Y; Patel J; Kong AN; Paulino R; Shih WJ; Lin Y; Rabson AB; Reddy BS; Conney AH
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5480-7. PubMed ID: 17875778
[TBL] [Abstract][Full Text] [Related]
7. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
Grothusen C; Bley S; Selle T; Luchtefeld M; Grote K; Tietge UJ; Drexler H; Schieffer B
Atherosclerosis; 2005 Sep; 182(1):57-69. PubMed ID: 16115475
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.
Kühnast S; van der Hoorn JW; van den Hoek AM; Havekes LM; Liau G; Jukema JW; Princen HM
J Hypertens; 2012 Jan; 30(1):107-16. PubMed ID: 22134386
[TBL] [Abstract][Full Text] [Related]
9. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
[TBL] [Abstract][Full Text] [Related]
10. MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
Nachtigal P; Pospisilova N; Pospechova K; Jamborova G; Kopecky M; Jaynes R; Briestensky J; Santar I; Smahelova A; Solichova D; Zdansky P; Semecky V
Life Sci; 2006 Mar; 78(17):1983-9. PubMed ID: 16305803
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis.
Nachtigal P; Jamborova G; Pospisilova N; Pospechova K; Solichova D; Zdansky P; Semecky V
J Pharm Pharm Sci; 2006; 9(2):222-30. PubMed ID: 16959191
[TBL] [Abstract][Full Text] [Related]
12. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
[TBL] [Abstract][Full Text] [Related]
13. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus.
Zhang L; Bertucci AM; Smith KA; Xu L; Datta SK
Arthritis Rheum; 2007 Dec; 56(12):4132-41. PubMed ID: 18050205
[TBL] [Abstract][Full Text] [Related]
14. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.
Massaro M; Zampolli A; Scoditti E; Carluccio MA; Storelli C; Distante A; De Caterina R
Cardiovasc Res; 2010 May; 86(2):311-20. PubMed ID: 19946014
[TBL] [Abstract][Full Text] [Related]
15. First head-to-head study comparing rosuvastatin and atorvastatin effects on the treatment of atherosclerosis.
Cardiovasc J Afr; 2008; 19(1):60. PubMed ID: 18320096
[No Abstract] [Full Text] [Related]
16. Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats.
Srinivas M; Annapurna A; Reddy YN
Indian J Exp Biol; 2008 Oct; 46(10):698-703. PubMed ID: 19024167
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
Sun Y; Liu J; Yang B; Sai X; Li T; Wang D; Zhou R
APMIS; 2014 Jun; 122(6):556-64. PubMed ID: 24164644
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
[TBL] [Abstract][Full Text] [Related]
19. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.
Gómez-Hernández A; Sánchez-Galán E; Ortego M; Martín-Ventura JL; Blanco-Colio LM; Tarín-Vicente N; Jiménez-Nacher JJ; López-Bescos L; Egido J; Tuñón J
Am J Cardiol; 2008 Jul; 102(1):12-8. PubMed ID: 18572029
[TBL] [Abstract][Full Text] [Related]
20. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
